Jessica G. C. A. M. Buijs-Gladdines
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jessica G. C. A. M. Buijs-Gladdines has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Bram van Wijk
Department of Pediatric Cardiothoracic Surgery, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, the Netherlands. 3
21 shared publications - Jules P. P. Meijerink
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
21 shared publications - Laurianne Trabut
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
21 shared publications - Markus J. van Roosmalen
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
21 shared publications - Rico Hagelaar
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
21 shared publications - Ruben van Boxtel
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
21 shared publications
Latest Publications
- Open Access
- 20 July 2026
- Published by Wiley in HemaSphere
- Vol. 10 (7) , e70439
Combined inhibition of de novo pyrimidine synthesis and ATR promotes ATF4‐mediated cell death in TP53 ‐deficient ALL
Mutations or deletions affecting the TP53 gene predict a dismal outcome in relapsed acute lymphoblastic leukemia (ALL). Loss of p53 function compromises the response to many anti‐leukemic therapies, underscoring the need for agents that are effective in TP53‐ deficient cells. Leukemic blasts depend on de novo pyrimidine synthesis to sustain proliferation, and the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) is essential for this pathway. While DHODH inhibitors (DHODHis) show preclinical anti‐leukemic activity, the efficacy in TP53 ‐deficient contexts has not been tested. Using both isogenic TP53 ‐wildtype and knock‐out cell line models and patient‐derived xenografts (PDXs), we show that dual inhibition of DHODH and Ataxia Telangiectasia and Rad3‐related (ATR) produces pronounced anti‐leukemic effects, irrespective of the TP53 status. Through integrated transcriptomic and metabolomic analyses, we show that combined inhibition of DHODH and ATR leads to a reduced flux of glucose into the TCA cycle, accompanied by an increase in oxidative stress. This metabolic phenotype triggers cell death through a mechanism converging on Activating Transcription Factor 4 (ATF4), a key integrator of cellular responses to metabolic and oxidative stress, which operates largely independently of p53. Taken together, our findings identify ATF4‐mediated cell death as a previously unrecognized vulnerability in TP53 ‐deficient ALL.
- 20 July 2026
- Published by Wiley in HemaSphere
- Vol. 10 (7) , e70439
Open AccessCombined inhibition of de novo pyrimidine synthesis and ATR promotes ATF4‐mediated cell death in TP53 ‐deficient ALL
Mutations or deletions affecting the TP53 gene predict a dismal outcome in relapsed acute lymphoblastic leukemia (ALL). Loss of p53 function compromises the response to many anti‐leukemic therapies, underscoring the need for agents that are effective in TP53‐ deficient cells. Leukemic blasts depend on de novo pyrimidine synthesis to sustain proliferation, and the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) is essential for this pathway. While DHODH inhibitors (DHODHis) show preclinical anti‐leukemic activity, the efficacy in TP53 ‐deficient contexts has not been tested. Using both isogenic TP53 ‐wildtype and knock‐out cell line models and patient‐derived xenografts (PDXs), we show that dual inhibition of DHODH and Ataxia Telangiectasia and Rad3‐related (ATR) produces pronounced anti‐leukemic effects, irrespective of the TP53 status. Through integrated transcriptomic and metabolomic analyses, we show that combined inhibition of DHODH and ATR leads to a reduced flux of glucose into the TCA cycle, accompanied by an increase in oxidative stress. This metabolic phenotype triggers cell death through a mechanism converging on Activating Transcription Factor 4 (ATF4), a key integrator of cellular responses to metabolic and oxidative stress, which operates largely independently of p53. Taken together, our findings identify ATF4‐mediated cell death as a previously unrecognized vulnerability in TP53 ‐deficient ALL.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Transient Differentiation-State Plasticity Occurs during Acute Lymphoblastic Leukemia Initiation
Table 4: WGS file and sequencing information
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Transient Differentiation-State Plasticity Occurs during Acute Lymphoblastic Leukemia Initiation
Table 4: WGS file and sequencing information
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Transient Differentiation-State Plasticity Occurs during Acute Lymphoblastic Leukemia Initiation
Table 3: List antibodies used for CITE sequencing
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Transient Differentiation-State Plasticity Occurs during Acute Lymphoblastic Leukemia Initiation
Table 3: List antibodies used for CITE sequencing
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Transient Differentiation-State Plasticity Occurs during Acute Lymphoblastic Leukemia Initiation
Table 1: Patient information and flow cytometry parameters healthy thymic donors
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Transient Differentiation-State Plasticity Occurs during Acute Lymphoblastic Leukemia Initiation
Table 1: Patient information and flow cytometry parameters healthy thymic donors
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Transient Differentiation-State Plasticity Occurs during Acute Lymphoblastic Leukemia Initiation
Table 2: Patient information and flow cytometry parameters T-ALL samples.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Transient Differentiation-State Plasticity Occurs during Acute Lymphoblastic Leukemia Initiation
Table 2: Patient information and flow cytometry parameters T-ALL samples.
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Data from Transient Differentiation-State Plasticity Occurs during Acute Lymphoblastic Leukemia Initiation
Leukemia is characterized by oncogenic lesions that result in a block of differentiation, whereas phenotypic plasticity is retained. A better understanding of how these two phenomena arise during leukemogenesis in humans could help inform diagnosis and treatment strategies. Here, we leveraged the well-defined differentiation states during T-cell development to pinpoint the initiation of T-cell acute lymphoblastic leukemia (T-ALL), an aggressive form of childhood leukemia, and study the emergence of phenotypic plasticity. Single-cell whole genome sequencing of leukemic blasts was combined with multiparameter flow cytometry to couple cell identity and clonal lineages. Irrespective of genetic events, leukemia-initiating cells altered their phenotypes by differentiation and dedifferentiation. The construction of the phylogenies of individual leukemias using somatic mutations revealed that phenotypic diversity is reflected by the clonal structure of cancer. The analysis also indicated that the acquired phenotypes are heritable and stable. Together, these results demonstrate a transient period of plasticity during leukemia initiation, where phenotypic switches seem unidirectional.Significance: A method merging multicolor flow cytometry with single-cell whole genome sequencing to couple cell identity with clonal lineages uncovers differentiation-state plasticity in leukemia, reconciling blocked differentiation with phenotypic plasticity in cancer.
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Transient Differentiation-State Plasticity Occurs during Acute Lymphoblastic Leukemia Initiation
Leukemia is characterized by oncogenic lesions that result in a block of differentiation, whereas phenotypic plasticity is retained. A better understanding of how these two phenomena arise during leukemogenesis in humans could help inform diagnosis and treatment strategies. Here, we leveraged the well-defined differentiation states during T-cell development to pinpoint the initiation of T-cell acute lymphoblastic leukemia (T-ALL), an aggressive form of childhood leukemia, and study the emergence of phenotypic plasticity. Single-cell whole genome sequencing of leukemic blasts was combined with multiparameter flow cytometry to couple cell identity and clonal lineages. Irrespective of genetic events, leukemia-initiating cells altered their phenotypes by differentiation and dedifferentiation. The construction of the phylogenies of individual leukemias using somatic mutations revealed that phenotypic diversity is reflected by the clonal structure of cancer. The analysis also indicated that the acquired phenotypes are heritable and stable. Together, these results demonstrate a transient period of plasticity during leukemia initiation, where phenotypic switches seem unidirectional.Significance: A method merging multicolor flow cytometry with single-cell whole genome sequencing to couple cell identity with clonal lineages uncovers differentiation-state plasticity in leukemia, reconciling blocked differentiation with phenotypic plasticity in cancer.
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Transient Differentiation-State Plasticity Occurs during Acute Lymphoblastic Leukemia Initiation
Supplementary Table 5 from Transient Differentiation-State Plasticity Occurs during Acute Lymphoblastic Leukemia Initiation
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Transient Differentiation-State Plasticity Occurs during Acute Lymphoblastic Leukemia Initiation
Supplementary Table 5 from Transient Differentiation-State Plasticity Occurs during Acute Lymphoblastic Leukemia Initiation